StimOxyGen is a spin-out from Ulster University developing cancer treatments that deliver oxygen directly to tumours to enhance the effectiveness of radiotherapy and immunotherapy. Its lead candidate is intended as an adjunct therapy to radiotherapy and has shown significant tumour reduction in preclinical studies across multiple cancer types. The company will initially focus on pancreatic cancer, which has limited treatment options and a poor five-year survival rate. StimOxyGen is led by CEO Sian Farrell, CSO Professor Anthony McHale and Non-Executive Director Dr Les Russell. The company raised £1.5M and plans to use the funds to advance key preclinical studies, scale up manufacturing and expand its team as it moves toward clinical translation.

Total raised

$2M

Funding rounds

1

Latest round

Equity

Latest activity

Mar 2025